Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
- 1 February 1992
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 339 (8791) , 441-445
- https://doi.org/10.1016/0140-6736(92)91054-c
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- HeparinNew England Journal of Medicine, 1991
- Prevention of Deep Vein Thrombosis after Elective Hip SurgeryAnnals of Internal Medicine, 1991
- Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinEuropean Journal of Clinical Pharmacology, 1990
- Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous ThrombosisNew England Journal of Medicine, 1990
- Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the RabbitThrombosis and Haemostasis, 1989
- Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.Circulation, 1989
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- SAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISMThe Lancet, 1986
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Low-Molecular-Weight HeparinNew England Journal of Medicine, 1986